A multicenter, randomized, double-blind clinical trial examining the effect of oral human recombinant epidermal growth factor on the healing of duodenal ulcers

Scandinavian Journal of Gastroenterology

Volumn 35, Issue 10, 2000, Pages 1016-1022

  Palomino, A ^a   Hernandez Bernal, F ^a   Haedo, W ^a   Franco, S ^a   Mas, J A ^a   Fernandez, J A ^a   Soto, G ^a   Alonso, A ^a   Gonzalez, T ^a   Lopez Saura, P ^a  

^a Center for Biological Research Cuba   (Cuba)

Author keywords

Clinical trial; Duodenal ulcer; Epidermal growth factor; Healing; Oral route

Indexed keywords

PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUODENOSCOPY; DUODENUM ULCER; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULCER HEALING;

EID: 0033773185     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655200451126     Document Type: Article

References (41)

1. Induction of a novel epidermal growth factor secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells
2. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer
3. Role of epidermal growth factor in gastroprotection and ulcer healing
4. The effect of route of delivery of urogastrone on intestinal regeneration
5. Epidermal growth factor in the gastroprotective and ulcer-healing actions of sucralfate in rats
6. Transforming growth factor alpha and epidermal growth factor in protection and healing of gastric mucosal injury
7. Epidermal growth factor promotes the chemotactic migration of culture rat intestinal epithelial cells
8. Proliferative effects of urogastrone-EGF on the intestinal epithelium
9. The contribution of the C-terminal undecapeptide sequence of urogastrone-epidermal growth factor to its biological action
10. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology
11. Role of salivary epidermal growth factor in the maintenance of physiochemical characteristics of oral and gastric mucosal mucus coat
12. Epidermal growth factor stimulates synthesis and secretion of mucus glycoproteins in human gastric mucosa
13. Transforming growth factor and epidermal growth factor levels in normal human gastrointestinal mucosa
14. Widespread distribution of human epidermal growth factor in human tissues and organs under normal and tumorous conditions immunohistochemical studies with the use of polyclonal and monoclonal antibodies
15. Human recombinant epidermal growth factor accelerate the burns healing in children. Double blind study
16. Use of human recombinant epidermal growth factor in silver sulfadiazine cream in the treatment of burned patients
17. Human recombinant epidermal growth factor in the treatment of radiogenic ulcers
18. Epidermal Growth Factor protects against carbon tetrachloride-induced hepatic injury
19. Epidermal growth factor prevents multi-organ failure induced by thioacetamide
20. Progresses in non clinical studies of the human recombinant epidermal growth factor in Cuba
21. Characterization of the epidermal growth factor receptor in the gastric mucosa
22. Oral human recombinant epidermal growth factor in the treatment of patients with duodenal ulcer
23. Epidermal growth factor and transforming growth factor alpha
24. Radioimmunoassay of epidermal growth factor in human saliva and gastric juice
25. Radioimmunoassay of human epidermal growth factor levels in human body fluids
26. Epidermal growth factor receptor: Structure and regulation
27. Specific receptors for epidermal growth factor in rat intestinal microvillus membranes
28. The epidermal growth factor is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract
29. The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat
30. Gastric cancer risk in relation to Helicobacter pylori infection and subtypes of intestinal metaplasia
31. Epidermal growth factor and transforming growth factor alpha in duodenal ulcer and non-ulcer dyspepsia patients before and after Helicobacter pylori eradication
32. Susceptibility of growth factors to degradation by Helicobacter pylori protease: Effect of ebrotidine and sucralfate
33. Gastric ulcer treatment with intravenous human epidermal growth factor: A double-blind controlled clinical study
34. Current trends in the pharmacotherapy for peptic ulcer disease
35. Helicobacter pylori associated with a high prevalence of duodenal ulcer disease and a low prevalence of gastric cancer in a developing nation
36. Effects of Helicobacter pylori gastritis on gastric secretion in healthy human beings
37. Is antibacterial therapy against Campylobacter pylori useful in the treatment of indigestion and chronic peptic ulceration?
38. Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro
39. Enhancement of gastric mucosal epidermal growth factor and platelet-derived growth factor receptor expression by sucralfate
40. Gastric mucosal EGF and PDGF receptor expression with ulcer healing by ebrotidine
41. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist